NeOnc Technologies Achieves Major Milestone in Development of NEO212 Brain Cancer Treatment

NEONC Technologies Announces Near Completion of Phase I Enrollment for Neo212 Brain Cancer Therapy

BOSTON, MA / ACCESSWIRE / April 25, 2022 / NEONC Technologies, a biotechnology company developing innovative therapies for cancer and other diseases, announced today that it has reached near completion of Phase I enrollment for Neo212, its novel brain cancer therapy.

Neo212 is a first-in-class, targeted therapy designed to selectively kill cancer cells while sparing healthy brain tissue. The Phase I clinical trial is evaluating the safety, tolerability, and efficacy of Neo212 in patients with recurrent or progressive brain gliomas.

"We are thrilled to announce the near completion of Phase I enrollment for Neo212, which marks a significant milestone in our mission to bring innovative therapies to patients with brain cancer," said Dr. [Name], CEO of NEONC Technologies. "The progress we've seen in this trial has been encouraging, and we look forward to reporting top-line data later this year."

The Phase I trial is a dose-escalation study designed to determine the maximum tolerated dose (MTD) of Neo212. Patients in the trial have received a range of doses, from 10 to 50 mg, and will continue to be monitored for safety and efficacy.

NEONC Technologies is committed to developing therapies that address the significant unmet needs in brain cancer treatment. Neo212 has the potential to offer a new approach to treating this devastating disease, which is characterized by limited treatment options and poor patient outcomes.

About NEONC Technologies NEONC Technologies is a biotechnology company dedicated to developing innovative therapies for cancer and other diseases. The company's pipeline includes Neo212, a novel brain cancer therapy, and other promising compounds in various stages of development. For more information, please visit our website at [website URL].

Contact: [Name] [Email] [Phone]